Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L39 (RPL39)
- Target
- RPL39
- Molecular classification
- Ribosomal protein, Structural constituent of ribosome, S39E family of ribosomal proteins, Other: Not an enzyme, receptor, transporter, or transcription factor
01
Overview
Ribosomal protein L39 is a small, highly basic structural component of the 60S large subunit of eukaryotic ribosomes, encoded by the RPL39 gene and located in the cytoplasm[1][4][5]. It plays a critical role in catalyzing cellular protein synthesis and maintaining ribosome structure. The protein is a member of the S39E family and is co-transcribed with the U69 small nucleolar RNA gene in humans. RPL39 is essential for organismal growth and viability, with disrupted function linked to defects in cell proliferation, embryonic development, and some cancers[8]. There are multiple pseudogenes of RPL39 scattered throughout the genome. ENSG00000258627 refers to a pseudogene, not the coding sequence for RPL39[7].
- Other names
- RPL39Ribosomal protein L3960S ribosomal protein L39RL39_HUMAN (UniProt)
02
Mechanism of action
Not applicable; no known drugs directly target RPL39.
03
Biological functions
Catalyzes protein synthesis as part of the large 60S ribosomal subunitRNA bindingStructural support for ribosome biogenesis and functionCell cycle and proliferation (as consequence of its involvement in protein synthesis)
04
Disease associations
Cancer (RPL39 and its paralogs have been linked to certain cancer types, though RPL39 is not a classical cancer target)Nervous system developmentCell migration/invasion in placental disease (e.g., preeclampsia)Other (limited direct evidence as a primary disease driver)
05
Safety considerations
Targeting ribosomal proteins generally presents safety concerns due to their essential role in protein synthesis, leading to potentially severe cytotoxic effects in healthy tissues. No direct therapeutic interventions are in use for RPL39.
06
Interacting drugs
None known; there are no approved drugs directly targeting ribosomal protein L39 specifically.
07
Biomarkers
RPL39 expression may have biomarker potential in some cancers and placental disease states but is not established or commonly used clinically
Beyond the preview
Go deeper on Ribosomal protein L39 (RPL39).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ribosomal protein L39 (RPL39).